Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents
AssigneeBiPar Sciences, Inc.
InventorsBarry M. Sherman, Charles Bradley, Valeria S. Ossovskaya
Life of this patent
Estimating the term…
Abstract
In one aspect, the present invention provides a method of treating breast cancer that is negative for at least one of ER, PR, or HER2, comprising administering to a subject at least one PARP inhibitor. In another aspect, the present invention provides a method of treating breast cancer comprising administering to a subject at least one PARP inhibitor in combination with at least one anti-tumor agent.
Claims10
A method of treating breast cancer that is negative for estrogen receptor (“ER”), progesterone receptor (“PR”), and human epidermal growth factor 2 receptor (“HER2”) in a patient, comprising administering to the patient having breast cancer that is negative for ER, PR and HER2 an effective amount of 4-iodo-3-nitrobenzamide or a metabolite or a pharmaceutically acceptable salt thereof, gemcitabine, and carboplatin.
Dependencies are inferred from the claim text.